Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry L Ng

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Cancer|December 15, 2018
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancerTerry L Ng, Yiwei Liu, Anastasios Dimou, et al.
Current Oncology (Toronto, Ont.)|August 25, 2023
A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast CancerRicardo Fernandes, Terry L Ng, Mashari Jemaan Alzahrani, et al.
Journal of Bone Oncology|March 8, 2021
Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalationSharon McGee, Mashari AlZahrani, Carol Stober, et al.
Current Oncology (Toronto, Ont.)|June 2, 2021
Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate CancerMegan M Tu, Mark Clemons, Carol Stober, et al.
Current Oncology (Toronto, Ont.)|December 23, 2021
Experiences and Perceptions of Older Adults with Lower-Risk Hormone Receptor-Positive Breast Cancer about Adjuvant Radiotherapy and Endocrine Therapy: A Patient SurveyMarie-France Savard, Mashari Jemaan Alzahrani, Deanna Saunders, et al.
Current Oncology (Toronto, Ont.)|March 27, 2024
The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer CareAna-Alicia Beltran-Bless, Mark Clemons, Lisa Vandermeer, et al.
Current Opinion in Supportive and Palliative Care|October 14, 2025
Survival prediction in metastatic breast cancer using artificial intelligence: a scoping reviewShely Kagan, Lyndsey Huynh, Caro Strickland, et al.
Current Oncology (Toronto, Ont.)|December 23, 2021
A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast CancerSusan Dent, Dean Fergusson, Olexiy Aseyev, et al.
Clinical Lung Cancer|October 10, 2018
Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With PonatinibTerry L Ng, Hui Yu, Derek E Smith, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expressionShengxiang Ren, Qinrui Tian, Nadav Amar, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Cancer|December 15, 2018
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancerTerry L Ng, Yiwei Liu, Anastasios Dimou, et al.
Current Oncology (Toronto, Ont.)|August 25, 2023
A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast CancerRicardo Fernandes, Terry L Ng, Mashari Jemaan Alzahrani, et al.
Journal of Bone Oncology|March 8, 2021
Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalationSharon McGee, Mashari AlZahrani, Carol Stober, et al.
Current Oncology (Toronto, Ont.)|June 2, 2021
Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate CancerMegan M Tu, Mark Clemons, Carol Stober, et al.
Current Oncology (Toronto, Ont.)|December 23, 2021
Experiences and Perceptions of Older Adults with Lower-Risk Hormone Receptor-Positive Breast Cancer about Adjuvant Radiotherapy and Endocrine Therapy: A Patient SurveyMarie-France Savard, Mashari Jemaan Alzahrani, Deanna Saunders, et al.
Current Oncology (Toronto, Ont.)|March 27, 2024
The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer CareAna-Alicia Beltran-Bless, Mark Clemons, Lisa Vandermeer, et al.
Current Opinion in Supportive and Palliative Care|October 14, 2025
Survival prediction in metastatic breast cancer using artificial intelligence: a scoping reviewShely Kagan, Lyndsey Huynh, Caro Strickland, et al.
Current Oncology (Toronto, Ont.)|December 23, 2021
A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast CancerSusan Dent, Dean Fergusson, Olexiy Aseyev, et al.
Clinical Lung Cancer|October 10, 2018
Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With PonatinibTerry L Ng, Hui Yu, Derek E Smith, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expressionShengxiang Ren, Qinrui Tian, Nadav Amar, et al.
Pageof 5